Western blot showed that Erlotinib significantly inhibited EGFR downstream signaling pathway-related protein expression and phosphorylation levels, and subsequently reduced the CCL2 expression in GBM cells (Figure 5D,E). Here, CCL2 is linked to glioblastoma.